These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 9869199)
1. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Legouffe E; Rodriguez C; Picot MC; Richard B; Klein B; Rossi JF; Commes T Leuk Lymphoma; 1998 Oct; 31(3-4):351-7. PubMed ID: 9869199 [TBL] [Abstract][Full Text] [Related]
2. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913 [TBL] [Abstract][Full Text] [Related]
3. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma. Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892 [TBL] [Abstract][Full Text] [Related]
4. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma]. Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831 [TBL] [Abstract][Full Text] [Related]
5. Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma. Herishanu Y; Perry C; Braunstein R; Metser U; Goor O; Rogowski O; Berliner S; Polliack A; Naparstek E Eur J Haematol; 2007 Aug; 79(2):150-4. PubMed ID: 17635239 [TBL] [Abstract][Full Text] [Related]
6. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Pavlidis AN; Kalef-Ezra J; Bourantas LC; Lambrou A; Mavridis A Int J Biol Markers; 1993; 8(1):14-20. PubMed ID: 8496627 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of some biochemical markers as prognostic factors in malignant lymphoma. Khalifa KA; Alkilani AA; Ismail H; Soliman MA J Egypt Natl Canc Inst; 2008 Mar; 20(1):47-54. PubMed ID: 19847281 [TBL] [Abstract][Full Text] [Related]
8. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Fayad L; Cabanillas F; Talpaz M; McLaughlin P; Kurzrock R Leuk Lymphoma; 1998 Aug; 30(5-6):563-71. PubMed ID: 9711918 [TBL] [Abstract][Full Text] [Related]
9. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma. Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of serum IL-6 level in monoclonal gammopathies. DuVillard L; Guiguet M; Casasnovas RO; Caillot D; Monnier-Zeller V; Bernard A; Guy H; Solary E Br J Haematol; 1995 Feb; 89(2):243-9. PubMed ID: 7873373 [TBL] [Abstract][Full Text] [Related]
11. Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin's lymphoma patients. Soydinc HO; Guney N; Basaran M; Duranyildiz D; Yasasever V Genet Mol Res; 2016 Jul; 15(3):. PubMed ID: 27525895 [TBL] [Abstract][Full Text] [Related]
12. Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value. Uskudar Teke H; Gulbas Z; Bal C J BUON; 2014; 19(1):191-7. PubMed ID: 24659663 [TBL] [Abstract][Full Text] [Related]
13. [Diagnostic and prognostic value of interleukin-6 in malignant non-Hodgkin's lymphomas]. Serebriakov NB; Novik AA; Shamanskiĭ SV; Krivolapov IuA; Voloshin SV; D'iakova VV; Snetkova IG; Katkova IV; Zhiburt EB Vestn Ross Akad Med Nauk; 1998; (10):32-6. PubMed ID: 9846110 [TBL] [Abstract][Full Text] [Related]
14. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma. Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592 [TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of erythrocyte sedimentation rate, C-reactive protein and serum lactate dehydrogenase levels in the diagnosis, prognosis and treatment monitoring of children suffering from cancer]. Bień E; Balcerska A Med Wieku Rozwoj; 2004; 8(4 Pt 2):1081-9. PubMed ID: 15951603 [TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blay JY; Burdin N; Rousset F; Lenoir G; Biron P; Philip T; Banchereau J; Favrot MC Blood; 1993 Oct; 82(7):2169-74. PubMed ID: 8400266 [TBL] [Abstract][Full Text] [Related]
17. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma. Zidan J; Hussein O; Basher W; Zohar S Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095 [TBL] [Abstract][Full Text] [Related]
18. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels. Benboubker L; Valat C; Linassier C; Cartron G; Delain M; Bout M; Fetissof F; Lefranq T; Lamagnere JP; Colombat P Ann Oncol; 2000 Nov; 11(11):1485-91. PubMed ID: 11142490 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Niitsu N; Okamato M; Nakamine H; Yoshino T; Tamaru J; Nakamura S; Higashihara M; Hirano M Eur J Haematol; 2002 Feb; 68(2):91-100. PubMed ID: 12038454 [TBL] [Abstract][Full Text] [Related]
20. Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma. Pérez-Encinas M; Quintas A; Bendaña A; Rabuñal MJ; Bello JL Leuk Lymphoma; 1999 May; 33(5-6):551-8. PubMed ID: 10342582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]